Literature DB >> 6234273

Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

G J Duckworth, J D Williams.   

Abstract

The clinical use of nalidixic acid has been hampered by the rapid appearance of resistant variants. This study compares the frequency of appearance of resistant variants to nalidixic acid and norfloxacin, a new quinolone-carboxylic acid with superior antimicrobial activity. We found a lower frequency of appearance of resistant variants with norfloxacin, although there was some cross-resistance between the two drugs. A gradation in this frequency was also noted between the species of Gram-negative rods tested, so that larger numbers of resistant variants appeared with the non-fermenters.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234273     DOI: 10.1093/jac/13.suppl_b.33

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

Review 1.  The prevention of antibiotic resistance during treatment.

Authors:  J D Williams; A M Sefton
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Cross-resistance and cross-susceptibility between fluoroquinolone agents.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

3.  In vitro induction of ciprofloxacin resistance in coagulase-negative staphylococci.

Authors:  J W Hartley; B A Oppenheim
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

4.  The place of quinolones in antibacterial therapy in hospitals.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

5.  Resistance to quinolones.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

Review 6.  Quo vadis with bacterial resistance?

Authors:  J D Williams
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 8.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

9.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

Authors:  P Heisig; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.